Fractyl is presenting the latest results from its trial of a gene therapy called Rejuva in mice at the annual meeting of the Obesity Society, called ObesityWeek, which is being held in Atlanta this week
You can also manage them with lifestyle notifications and home remedies
Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
Takeaways GLP-1s have shown numerous benefits for people who have diabetes, as well as for those who have obesity
Theres no separate membership or platform fee
Compounded Semaglutide contains the same active ingredient as brand-name medications, but it is made by licensed compounding pharmacies instead of mass-produced by large pharmaceutical companies
